Bind Therapeutics (BIND) 0.40 $BIND
BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.
BusinessWire - Thu May 19, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., an affiliate of Hercules Capital (NYSE: HTCG), for the use of cash collateral through July 8, 2016 subject to certain agreed upon terms and conditions. As part of the agreement negotiated under BIND's voluntary chapter 11 filing, the Company has agreed, among other things, to pay-down $4 million in principal on the existing principal loan balance of approximately $12.4 million.
BIND: 0.40 (-0.01)
Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS(R) to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
BusinessWire - Tue May 10, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced the publication of detailed methods for its hydrophobic ion pairing (HIP) approach that can be applied to a wide range of ionizable molecules, greatly increasing the diversity of payloads that can be encapsulated in ACCURINS(R). Previous data demonstrated the potential of ACCURINS(R) to deliver the aurora B kinase inhibitor AZD2811 to tumor sites and in this publication, researchers from BIND Therapeutics and AstraZeneca describe the preparation of nanoparticles encapsulating AZD2811 in detail and characterize their pharmacokinetics, tolerability and mechanisms of tumor growth inhibition in preclinical models. The data are published in the May 10, 2016 issue of the Journal of Controlled Release.
BIND: 0.40 (-0.01)
Bind Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 6:23AM CDT
CAMBRIDGE, Mass. (AP) _ Bind Therapeutics Inc. (BIND) on Monday reported a loss of $12.7 million in its first quarter.
BIND: 0.40 (-0.01)
BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 09, 6:00AM CDT
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today reported financial results for the first quarter ended March 31, 2016 and provided a business update.
BIND: 0.40 (-0.01)
Is a Surprise Coming for BIND Therapeutics (BIND) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 7:36AM CDT
BIND Therapeutics (BIND) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
BIND: 0.40 (-0.01)
BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor Immunity
BusinessWire - Thu May 05, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins(R) that selectively bind and interact with identified targets. Under terms of the collaboration, BIND will utilize Nanofitins(R) as targeting ligand components for ACCURINS(R) designed to bind immuno-oncology targets. Upon achievement of proof-of-concept, BIND anticipates expanding the collaboration to develop ACCURINS(R) that incorporate unique combinations of immuno-oncology targeting ligands and new classes of payloads, including oligonucleotides and molecularly targeted therapies.
BIND: 0.40 (-0.01)
What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 32.45 (-1.11), SNTA: 0.35 (-0.01), JAZZ: 150.76 (-5.26), BIND: 0.40 (-0.01)
What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), HZNP: 17.88 (-0.65), BIND: 0.40 (-0.01)
BIND Therapeutics to Report First Quarter 2016 Financial Results on May 9, 2016
BusinessWire - Tue May 03, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced it will host a conference call and audio webcast on May 9, 2016, at 8:30 a.m. ET to report first quarter 2016 financial results and provide a business update.
BIND: 0.40 (-0.01)
Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 56.81 (-0.37), BIND: 0.40 (-0.01), CHMA: 2.91 (-0.23), FOLD: 6.05 (-0.66)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03), BIND: 0.40 (-0.01), FOLD: 6.05 (-0.66)
DaVita (DVA) Likely to Top Q1 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:08AM CDT
We expect DaVita HealthCare Partners Inc. (DVA) to beat expectations when it reports first-quarter 2016 results on May 4, after the market closes.
ACET: 22.52 (-0.15), BDX: 169.29 (-0.94), DVA: 76.08 (-1.13), BIND: 0.40 (-0.01)
BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding
BusinessWire - Mon May 02, 5:00AM CDT
BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
BIND: 0.40 (-0.01)
PeptiDream Announces Research Collaboration with BIND Therapeutics
BusinessWire - Wed Apr 06, 9:33AM CDT
PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream"
(TOKYO:4587) announced today that it has entered into a research collaboration with US-based BIND Therapeutics (NASDAQ: BIND). PeptiDream intends to use its Peptide Discovery Platform System (PDPS) technology to identify macrocyclic peptides that can be utilized as biologically active targeting ligands with BIND's proprietary Accurin nanoparticles (ACCURINS(R)). BIND has selected targeting ligands of interest to accelerate the Company's innovative medicines strategy focused on products that elicit tumor cell death and modulate the tumor microenvironment to maximize clinical benefit for patients.
BIND: 0.40 (-0.01)
BIND Therapeutics Reports Phase 2 Data from iNSITE 1 and iNSITE 2 Trials with BIND-014 and Provides Strategic Update
BusinessWire - Wed Apr 06, 8:25AM CDT
--Company to implement restructuring plan in line with previously announced shift in R&D strategy to leverage the platform to develop innovative medicines and initiate a review of financial and strategic alternatives
BIND: 0.40 (-0.01)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 4.64 (-0.04), BIND: 0.40 (-0.01), MNKD: 1.01 (-0.02), KERX: 5.93 (-0.12)
BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS(R) Platform
BusinessWire - Tue Mar 15, 6:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today reported financial results for the fourth quarter and full year 2015. Additionally, the Company announced a shift in its research and discovery strategy to focus on the development of innovative medicines, primarily in cancer. Moving forward, BIND plans to focus on the development of therapeutics that leverage the ability of ACCURINS(R) to incorporate novel combinations of targeting ligands and unique payloads including oligonucleotides and potent kinase inhibitors, creating synergistic properties in a single particle.
BIND: 0.40 (-0.01)
BIND Therapeutics to Report Fourth Quarter and Year-End 2015 Financial Results on March 15, 2016
BusinessWire - Wed Mar 09, 7:00AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced it will host a conference call and live audio webcast on March 15, 2016, at 8:30 a.m. ET to report fourth quarter and year-end 2015 financial results.
BIND: 0.40 (-0.01)
AZD2811 ACCURINS(R) Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies
BusinessWire - Wed Feb 10, 3:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing innovative therapeutics called ACCURINS(R), today announced the publication of data highlighting the ability of ACCURIN polymeric nanoparticle technology to utilize hydrophobic ion pairing and improve the therapeutic index of a molecularly targeted anti-cancer drug. Previous efforts with nanotechnology have focused almost exclusively on encapsulating chemotherapy payloads; the publication describes one of the first efforts to apply nanotechnology to a molecular targeted agent. Results highlight the potential for ACCURINS(R) to control release kinetics and provide increased concentration of an aurora B kinase inhibitor, AZD2811, at tumor sites resulting in prolonged pharmacodynamic effects, superior tumor growth inhibition and a reduction in on-target but off-tissue toxicity. These data were published in the February 10, 2016 issue of Science Translational Medicine.
BIND: 0.40 (-0.01)
BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.
BusinessWire - Thu May 19, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., an affiliate of Hercules Capital (NYSE: HTCG), for the use of cash collateral through July 8, 2016 subject to certain agreed upon terms and conditions. As part of the agreement negotiated under BIND's voluntary chapter 11 filing, the Company has agreed, among other things, to pay-down $4 million in principal on the existing principal loan balance of approximately $12.4 million.
BIND: 0.40 (-0.01)
Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS(R) to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
BusinessWire - Tue May 10, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced the publication of detailed methods for its hydrophobic ion pairing (HIP) approach that can be applied to a wide range of ionizable molecules, greatly increasing the diversity of payloads that can be encapsulated in ACCURINS(R). Previous data demonstrated the potential of ACCURINS(R) to deliver the aurora B kinase inhibitor AZD2811 to tumor sites and in this publication, researchers from BIND Therapeutics and AstraZeneca describe the preparation of nanoparticles encapsulating AZD2811 in detail and characterize their pharmacokinetics, tolerability and mechanisms of tumor growth inhibition in preclinical models. The data are published in the May 10, 2016 issue of the Journal of Controlled Release.
BIND: 0.40 (-0.01)
Bind Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 6:23AM CDT
CAMBRIDGE, Mass. (AP) _ Bind Therapeutics Inc. (BIND) on Monday reported a loss of $12.7 million in its first quarter.
BIND: 0.40 (-0.01)
BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 09, 6:00AM CDT
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today reported financial results for the first quarter ended March 31, 2016 and provided a business update.
BIND: 0.40 (-0.01)
Is a Surprise Coming for BIND Therapeutics (BIND) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 7:36AM CDT
BIND Therapeutics (BIND) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
BIND: 0.40 (-0.01)
BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor Immunity
BusinessWire - Thu May 05, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins(R) that selectively bind and interact with identified targets. Under terms of the collaboration, BIND will utilize Nanofitins(R) as targeting ligand components for ACCURINS(R) designed to bind immuno-oncology targets. Upon achievement of proof-of-concept, BIND anticipates expanding the collaboration to develop ACCURINS(R) that incorporate unique combinations of immuno-oncology targeting ligands and new classes of payloads, including oligonucleotides and molecularly targeted therapies.
BIND: 0.40 (-0.01)
What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 32.45 (-1.11), SNTA: 0.35 (-0.01), JAZZ: 150.76 (-5.26), BIND: 0.40 (-0.01)
What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), HZNP: 17.88 (-0.65), BIND: 0.40 (-0.01)
BIND Therapeutics to Report First Quarter 2016 Financial Results on May 9, 2016
BusinessWire - Tue May 03, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced it will host a conference call and audio webcast on May 9, 2016, at 8:30 a.m. ET to report first quarter 2016 financial results and provide a business update.
BIND: 0.40 (-0.01)
Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 56.81 (-0.37), BIND: 0.40 (-0.01), CHMA: 2.91 (-0.23), FOLD: 6.05 (-0.66)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03), BIND: 0.40 (-0.01), FOLD: 6.05 (-0.66)
DaVita (DVA) Likely to Top Q1 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:08AM CDT
We expect DaVita HealthCare Partners Inc. (DVA) to beat expectations when it reports first-quarter 2016 results on May 4, after the market closes.
ACET: 22.52 (-0.15), BDX: 169.29 (-0.94), DVA: 76.08 (-1.13), BIND: 0.40 (-0.01)
BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding
BusinessWire - Mon May 02, 5:00AM CDT
BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
BIND: 0.40 (-0.01)
PeptiDream Announces Research Collaboration with BIND Therapeutics
BusinessWire - Wed Apr 06, 9:33AM CDT
PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream"
(TOKYO:4587) announced today that it has entered into a research collaboration with US-based BIND Therapeutics (NASDAQ: BIND). PeptiDream intends to use its Peptide Discovery Platform System (PDPS) technology to identify macrocyclic peptides that can be utilized as biologically active targeting ligands with BIND's proprietary Accurin nanoparticles (ACCURINS(R)). BIND has selected targeting ligands of interest to accelerate the Company's innovative medicines strategy focused on products that elicit tumor cell death and modulate the tumor microenvironment to maximize clinical benefit for patients. BIND: 0.40 (-0.01)
BIND Therapeutics Reports Phase 2 Data from iNSITE 1 and iNSITE 2 Trials with BIND-014 and Provides Strategic Update
BusinessWire - Wed Apr 06, 8:25AM CDT
--Company to implement restructuring plan in line with previously announced shift in R&D strategy to leverage the platform to develop innovative medicines and initiate a review of financial and strategic alternatives
BIND: 0.40 (-0.01)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 4.64 (-0.04), BIND: 0.40 (-0.01), MNKD: 1.01 (-0.02), KERX: 5.93 (-0.12)
BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS(R) Platform
BusinessWire - Tue Mar 15, 6:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today reported financial results for the fourth quarter and full year 2015. Additionally, the Company announced a shift in its research and discovery strategy to focus on the development of innovative medicines, primarily in cancer. Moving forward, BIND plans to focus on the development of therapeutics that leverage the ability of ACCURINS(R) to incorporate novel combinations of targeting ligands and unique payloads including oligonucleotides and potent kinase inhibitors, creating synergistic properties in a single particle.
BIND: 0.40 (-0.01)
BIND Therapeutics to Report Fourth Quarter and Year-End 2015 Financial Results on March 15, 2016
BusinessWire - Wed Mar 09, 7:00AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced it will host a conference call and live audio webcast on March 15, 2016, at 8:30 a.m. ET to report fourth quarter and year-end 2015 financial results.
BIND: 0.40 (-0.01)
AZD2811 ACCURINS(R) Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies
BusinessWire - Wed Feb 10, 3:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing innovative therapeutics called ACCURINS(R), today announced the publication of data highlighting the ability of ACCURIN polymeric nanoparticle technology to utilize hydrophobic ion pairing and improve the therapeutic index of a molecularly targeted anti-cancer drug. Previous efforts with nanotechnology have focused almost exclusively on encapsulating chemotherapy payloads; the publication describes one of the first efforts to apply nanotechnology to a molecular targeted agent. Results highlight the potential for ACCURINS(R) to control release kinetics and provide increased concentration of an aurora B kinase inhibitor, AZD2811, at tumor sites resulting in prolonged pharmacodynamic effects, superior tumor growth inhibition and a reduction in on-target but off-tissue toxicity. These data were published in the February 10, 2016 issue of Science Translational Medicine.
BIND: 0.40 (-0.01)
